cisapride has been researched along with Parkinson Disease in 8 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cisapride is a drug that causes increased release of acetylcholine in the myenteric plexus." | 5.29 | Cisapride treatment of constipation in Parkinson's disease. ( Jost, WH; Schimrigk, K, 1993) |
| "Five studies reported the use of cisapride and tegaserod in people with spinal cord injuries or Parkinson's disease." | 4.90 | Management of faecal incontinence and constipation in adults with central neurological diseases. ( Cody, JD; Coggrave, M; Norton, C, 2014) |
| "Five studies reported the use of cisapride and tegaserod in people with spinal cord injuries or Parkinson's disease." | 4.89 | Management of faecal incontinence and constipation in adults with central neurological diseases. ( Coggrave, M; Norton, C, 2013) |
| "Cisapride is a prokinetic drug that enhances gastric emptying by releasing acetylcholine from the myenteric plexus." | 2.68 | Effect of cisapride on response fluctuations in Parkinson's disease. ( Achiron, A; Djaldetti, R; Koren, M; Melamed, E; Ziv, I, 1995) |
| "Treatment with cisapride, a prokinetic drug, causes amelioration of these fluctuations." | 2.39 | Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease. ( Djaldetti, R; Melamed, E; Ziv, I, 1996) |
| "Cisapride (CIS) is a prokinetic agent that increases gastrointestinal motility in normal individuals and improves constipation in Parkinson's disease (PD)." | 1.29 | The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease. ( de Yebenes, JG; Mena, MA; Neira, WD; Sanchez, V, 1995) |
| "Cisapride is a drug that causes increased release of acetylcholine in the myenteric plexus." | 1.29 | Cisapride treatment of constipation in Parkinson's disease. ( Jost, WH; Schimrigk, K, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coggrave, M | 2 |
| Norton, C | 2 |
| Cody, JD | 1 |
| Jost, WH | 3 |
| Schimrigk, K | 3 |
| Neira, WD | 1 |
| Sanchez, V | 1 |
| Mena, MA | 1 |
| de Yebenes, JG | 1 |
| Djaldetti, R | 2 |
| Koren, M | 1 |
| Ziv, I | 2 |
| Achiron, A | 1 |
| Melamed, E | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neurogenic Bowel Dysfunction: Evaluation of the Effects of Osteopathic Manipulative Treatment in People With Central Nervous System Injury[NCT04127617] | 70 participants (Anticipated) | Interventional | 2019-10-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for cisapride and Parkinson Disease
| Article | Year |
|---|---|
Management of faecal incontinence and constipation in adults with central neurological diseases.
Topics: Adult; Central Nervous System Diseases; Cisapride; Constipation; Fecal Incontinence; Gastrointestina | 2013 |
Management of faecal incontinence and constipation in adults with central neurological diseases.
Topics: Central Nervous System Diseases; Cisapride; Constipation; Fecal Incontinence; Gastrointestinal Agent | 2014 |
Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Cisapride; Drug Therapy, Combination; Gastric Emptying; | 1996 |
2 trials available for cisapride and Parkinson Disease
| Article | Year |
|---|---|
The effect of cisapride on delayed colonic transit time in patients with idiopathic Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cisapride; Colon; Constipation; Cross-Over Studies; Double-Blind Method; Fe | 1994 |
Effect of cisapride on response fluctuations in Parkinson's disease.
Topics: Aged; Cisapride; Drug Therapy, Combination; Gastric Emptying; Humans; Levodopa; Middle Aged; Motor A | 1995 |
3 other studies available for cisapride and Parkinson Disease
| Article | Year |
|---|---|
The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease.
Topics: Aged; Cisapride; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Diseas | 1995 |
Cisapride treatment of constipation in Parkinson's disease.
Topics: Acetylcholine; Aged; Autonomic Nervous System; Cisapride; Constipation; Female; Humans; Male; Middle | 1993 |
Long-term results with cisapride in Parkinson's disease.
Topics: Aged; Cathartics; Cisapride; Constipation; Female; Humans; Male; Middle Aged; Parkinson Disease; Per | 1997 |